MXPA05008570A - Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion. - Google Patents

Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion.

Info

Publication number
MXPA05008570A
MXPA05008570A MXPA05008570A MXPA05008570A MXPA05008570A MX PA05008570 A MXPA05008570 A MX PA05008570A MX PA05008570 A MXPA05008570 A MX PA05008570A MX PA05008570 A MXPA05008570 A MX PA05008570A MX PA05008570 A MXPA05008570 A MX PA05008570A
Authority
MX
Mexico
Prior art keywords
tissue damage
ischemia
reperfusion injury
damage associated
preventing
Prior art date
Application number
MXPA05008570A
Other languages
English (en)
Inventor
Sek Chung Fung
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of MXPA05008570A publication Critical patent/MXPA05008570A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un metodo para prevenir o tratar el dano tisular asociado con la lesion por isquemia-reperfusion y reparacion de aneurisma aortica toracica-abdominal (TAAA) al administrar una cantidad suficiente para la prevencion o tratamiento del dano tisular de un inhibidor de complemento a un paciente que sufriria probablemente o sufre del dano tisular asociado con el dano por reperfusion-isquemia o con la reparacion de TAAA. Los inhibidores de complemento son de preferencia anticuerpos que se unen e inhiben a las proteinas de complemento involucradas en la formacion del complejo de ataque de membrana, de preferencia anticuerpos que inhiben MBL, MASP1, MASP2 y MASP3 en la ruta de lectina. Los inhibidores de complemento pueden emplearse solos o en combinacion para disminuir la morbididad y mortalidad causada por el dano tisular asociado con la lesion por isquemia-reperfusion y reparacion de TAAA.
MXPA05008570A 2003-02-21 2004-02-20 Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion. MXPA05008570A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44906903P 2003-02-21 2003-02-21
PCT/US2004/005136 WO2004075837A2 (en) 2003-02-21 2004-02-20 Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
MXPA05008570A true MXPA05008570A (es) 2005-11-04

Family

ID=32927493

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008570A MXPA05008570A (es) 2003-02-21 2004-02-20 Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion.

Country Status (9)

Country Link
US (2) US20060140939A1 (es)
EP (2) EP1601377A4 (es)
JP (1) JP2006518749A (es)
CN (2) CN1750844B (es)
AU (1) AU2004216176B2 (es)
CA (1) CA2515453C (es)
HK (2) HK1084603A1 (es)
MX (1) MXPA05008570A (es)
WO (1) WO2004075837A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109908352A (zh) * 2012-06-18 2019-06-21 奥默罗斯公司 抑制masp-1和/或masp-2和/或masp-3的组合物和方法

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
DE60229416D1 (de) 2001-10-25 2008-11-27 Univ Emory Katheter für modifizierte Perfusion
US7827077B2 (en) 2003-05-02 2010-11-02 Visa U.S.A. Inc. Method and apparatus for management of electronic receipts on portable devices
EP1625166B1 (en) 2003-05-12 2015-04-08 Helion Biotech ApS Antibodies to masp-2
CA2524534C (en) * 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2011265532B2 (en) * 2004-06-10 2014-04-24 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
PT1753456T (pt) * 2004-06-10 2016-11-04 Univ Leicester Métodos para tratar condições associadas com a ativação do complemento dependente de masp-2
AU2013201565B2 (en) * 2004-06-10 2016-03-31 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
GB0412966D0 (en) * 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20080097385A1 (en) * 2004-12-22 2008-04-24 Jakob Vinten-Johansen Therapeutic Adjuncts to Enhance the Organ Protective Effects of Postconditioning
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2551202T5 (es) * 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
DK1965831T3 (da) * 2005-12-21 2011-10-24 Pharming Intellectual Pty Bv Anvendelse af C1-inhibitor til forebyggelse af iskæmi-reperfusionsskade
US8524453B2 (en) 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
PL3028716T3 (pl) 2006-10-10 2021-03-08 Regenesance B.V. Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
WO2009085475A1 (en) * 2007-12-21 2009-07-09 Sevrain Lionel C Method for detection and treatment of aneurysms
HUP0900319A2 (en) * 2009-05-25 2011-01-28 Eotvos Lorand Tudomanyegyetem New peptides, method of producing therof and use thereof
HUE030897T2 (en) * 2009-10-16 2017-06-28 Omeros Corp Procedures for Treatment of Disseminated Intravascular Coagulation by Inhibition of MASP-Dependent Complement Activation
CA2811091C (en) * 2010-03-02 2017-07-25 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin
WO2011112575A1 (en) * 2010-03-08 2011-09-15 Wake Forest University Health Sciences Keratin biomaterials for treatment of ischemia
CA2797856C (en) 2010-04-30 2018-09-18 Alexion Pharmaceuticals, Inc. Anti-c5a antibodies and methods for using the antibodies
WO2012006599A2 (en) * 2010-07-09 2012-01-12 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3287142B1 (en) 2011-04-08 2021-08-04 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
CN102304158B (zh) * 2011-05-20 2014-07-30 中国人民解放军第二军医大学 酰化黄酮苷化合物及其在制备补体抑制剂药物中的应用
KR20140064768A (ko) 2011-07-01 2014-05-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-프로퍼딘 항체 및 그의 용도
WO2013025941A1 (en) 2011-08-17 2013-02-21 Keranetics Llc Low protein percentage gelling compositions
WO2013025928A2 (en) 2011-08-17 2013-02-21 Keranetics Llc Methods for extracting keratin proteins
CA2848510A1 (en) * 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN104114576B (zh) 2011-12-21 2017-04-05 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
HUE036930T2 (hu) * 2012-04-06 2018-08-28 Omeros Corp Készítmények és eljárások MASP-1 és/vagy MASP-3 gátlására paroxymalis nocturnalis hemoglobinürítés kezelésére
EP2904014A4 (en) 2012-10-04 2016-09-28 Novelmed Therapeutics Inc FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES
RS62243B9 (sr) 2012-11-15 2022-11-30 Apellis Pharmaceuticals Inc Analozi kompstatina sa produženim trajanjem dejstva i njihove kompozicije i postupci
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
US9827245B2 (en) 2013-03-15 2017-11-28 KeraNetics, LLC Keratin compositions comprising halofuginone
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
BR112016002845A2 (pt) 2013-08-12 2017-09-12 Genentech Inc composições e métodos para tratar condições associadas ao complemento
CN103788157B (zh) * 2014-02-14 2016-04-06 天津科技大学 绒毛白蜡中一种香豆素衍生物及其制备工艺和应用
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法
KR20180090785A (ko) 2015-10-07 2018-08-13 아펠리스 파마슈티컬스 인코포레이티드 투여 요법
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2019246367A1 (en) * 2018-06-22 2019-12-26 Omeros Corporation Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
WO2020115095A2 (en) * 2018-12-05 2020-06-11 Glycardial Diagnostics, S.L. Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CA3139209A1 (en) 2019-05-07 2020-11-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
WO2022096394A1 (en) 2020-11-04 2022-05-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
JP2024518724A (ja) * 2021-04-25 2024-05-02 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6086868A (en) * 1997-04-30 2000-07-11 Schering Corporation Method for treating or preventing ischemia-reperfusion injury
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7273925B1 (en) * 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
EP1140171A4 (en) * 1998-12-15 2002-03-13 Brigham & Womens Hospital METHODS AND PRODUCTS FOR REGULATING THE COMPLEMENT ACTIVATION ASSOCIATED WITH THE LECTIN COMPLEMENT SYSTEM
WO2000047194A2 (en) 1999-02-09 2000-08-17 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
CA2380979A1 (en) * 1999-08-13 2001-02-22 Brigham And Women's Hospital, Inc. Inhibitors of the lectin complement pathway (lcp) and their use
CA2391402A1 (en) * 1999-12-02 2001-06-07 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
CA2887012A1 (en) * 2000-07-13 2002-01-24 Helion Biotech Aps Masp-2, a complement-fixing enzyme, and uses for it
CA2433353C (en) 2000-12-28 2017-03-21 Altus Biologics, Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109908352A (zh) * 2012-06-18 2019-06-21 奥默罗斯公司 抑制masp-1和/或masp-2和/或masp-3的组合物和方法

Also Published As

Publication number Publication date
HK1150751A1 (en) 2012-01-13
CA2515453A1 (en) 2004-09-10
US20060140939A1 (en) 2006-06-29
CA2515453C (en) 2013-09-24
WO2004075837A3 (en) 2005-06-02
EP1601377A2 (en) 2005-12-07
EP2422812A1 (en) 2012-02-29
WO2004075837A2 (en) 2004-09-10
AU2004216176B2 (en) 2008-04-03
EP1601377A4 (en) 2009-07-15
CN101897969A (zh) 2010-12-01
US20090017031A1 (en) 2009-01-15
AU2004216176A1 (en) 2004-09-10
CN101897969B (zh) 2014-04-02
CN1750844B (zh) 2010-09-08
HK1084603A1 (en) 2006-08-04
CN1750844A (zh) 2006-03-22
JP2006518749A (ja) 2006-08-17

Similar Documents

Publication Publication Date Title
MXPA05008570A (es) Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion.
ATE525383T1 (de) Neue galactosidinhibitoren von galectinen
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
ATE429208T1 (de) Verfahren zur herstellung von hydrokolloiden
TW200727894A (en) Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation
CL2008001259A1 (es) Uso de una composicion que comprende un inhibidor del factor d del complemento para preparar un medicamento util para la inhibicion de la perdida de agudeza visual ociada con la degeneracion macular relacionada con la edad.
MX2009013332A (es) Inhibidores de ire-1 alfa.
PH12018500639A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
AR065083A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
MY151191A (en) Novel antibodies
ATE549359T1 (de) Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen
NO20071378L (no) Tiazolo-naftylsyrer.
ATE314062T1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
CL2009000985A1 (es) Composicion oftalmica que comprende entre 0,16 y 0,19% p/v de un galactomanano, alrededor de 0,7% p/v de un borato, cis-diol y menos de 5 ppm de concentracion de cationes divalentes; y su uso para lubricar el ojo.
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
PH12020552286A1 (en) Compositions and methods for treating inflammasome related diseases or conditions
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
WO2006041835A3 (en) Methods of inhibiting cell death or inflammation in a mammal
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
TW200626073A (en) Activated globular protein and its use in edible compositions
MX2011010131A (es) Metodos para la prevencion y tratamiento de daños tisulares asociados con una lesion por isquemia-reperfusion.
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза
UA86981C2 (ru) Применение производных ретинила для лечения офтальмических состояний

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights